Semantic Scholar uses AI to extract papers important to this topic.
Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly… Expand Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune… Expand Acalabrutinib is a new, irreversible Bruton tyrosine kinase (BTK) inhibitor, reported to be more selective than ibrutinib.[1… Expand Immunotherapy is becoming an accepted treatment modality for many patients with cancer and is now approved for use in platinum… Expand BACKGROUND
Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for… Expand More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class… Expand Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis… Expand Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds… Expand 4130Background: The importance of the tumor microenvironment in the biology of mPC has been increasingly recognized. However… Expand Ibrutinib, a first generation Btk inhibitor, is approved for the treatment of CLL and mantle cell lymphoma; known toxicities… Expand